GAS6 and COVID-19: In line with it, the AXL inhibitor gilteritinib, which is an FDA-approved drug for the treatment of acute myeloid leukemia, was recently demonstrated to possess antiviral efficacy against SARS-CoV-2 infection in Vero E6 cells, providing additional grounds for GAS6/AXL targeting as a promising anti-COVID-19 treatment [106].